28018523|t|Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC)
28018523|a|Stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) is considered standard of care in the medically inoperable patient population. Multiple methods of SBRT delivery exist including fiducial -based tumor tracking, which allows for smaller treatment margins and avoidance of patient immobilization devices. We explore the long-term clinical outcomes of this novel fiducial -based SBRT method. In this single institutional retrospective review, we detail the outcomes of medically inoperable pathologically confirmed stage I NSCLC. Patients were treated with the Cyberknife SBRT system using a planning target volume (PTV) defined as a 5-mm expansion from gross tumor volume (GTV) without creation of an internal target volume (ITV). Dose was delivered in three or five equal fractions of 10 to 20 Gy. Pretreatment and posttreatment pulmonary function test (PFT) changes and evidence of late radiological rib fractures were analyzed for the majority of patients. Actuarial local control, locoregional control, distant control, and overall survival were calculated using the Kaplan-Meier method. Sixty-one patients with a median age of 75 years were available for analysis. The majority (80 %) of patients were deemed to be medically inoperable due to underlying pulmonary dysfunction. Eleven patients (18 %) developed symptomatic pneumothoraces secondary to fiducial placement under CT guidance, which precipitously dropped to 0 % following transition to bronchoscopic fiducial placement. The 2-year rib fracture risk was 21.4 % with a median time to rib fracture of 2.9 years. PFTs averaged over all patients and parameters demonstrated small absolute declines, 5.7 % averaged PFT decline, at approximately 1 year of follow-up, but only the diffusing capacity of lung for carbon monoxide (DLCO) demonstrated a statistically significant decline (10.29 vs. 9.01 mL/min/mmHg, p = 0.01). Five-year local control, locoregional control, and overall surviva l were 87.6, 71.8, and 39.3 %, respectively. Despite reduced treatment margins and lack of patient immobilization, SBRT with fiducial -based tumor tracking achieves clinically comparable long-term outcomes to other linac -based SBRT approaches.
28018523	22	57	stereotactic body radiation therapy	T058	UMLS:C3896609
28018523	59	63	SBRT	T058	UMLS:C3896609
28018523	70	78	fiducial	T074	UMLS:C2826325
28018523	79	87	tracking	T082	UMLS:C0546881
28018523	103	137	stage I non-small cell lung cancer	T038	UMLS:C0278504
28018523	139	144	NSCLC	T038	UMLS:C0278504
28018523	146	181	Stereotactic body radiation therapy	T058	UMLS:C3896609
28018523	183	187	SBRT	T058	UMLS:C3896609
28018523	193	227	stage I non-small cell lung cancer	T038	UMLS:C0278504
28018523	229	234	NSCLC	T038	UMLS:C0278504
28018523	250	266	standard of care	T058	UMLS:C2936643
28018523	303	313	population	T098	UMLS:C1257890
28018523	315	331	Multiple methods	T058	UMLS:C0087111
28018523	335	339	SBRT	T058	UMLS:C3896609
28018523	340	348	delivery	T058	UMLS:C0011211
28018523	365	373	fiducial	T074	UMLS:C2826325
28018523	381	386	tumor	T038	UMLS:C0027651
28018523	387	395	tracking	T082	UMLS:C0546881
28018523	422	439	treatment margins	T017	UMLS:C0229985
28018523	457	487	patient immobilization devices	T058	UMLS:C0035260
28018523	514	531	clinical outcomes	T033	UMLS:C0243095
28018523	546	554	fiducial	T074	UMLS:C2826325
28018523	562	573	SBRT method	T058	UMLS:C3896609
28018523	583	603	single institutional	T092	UMLS:C1266869
28018523	688	697	confirmed	T033	UMLS:C0750484
28018523	698	711	stage I NSCLC	T038	UMLS:C0278504
28018523	727	739	treated with	T058	UMLS:C0332293
28018523	744	754	Cyberknife	T074	UMLS:C1300683
28018523	755	766	SBRT system	T058	UMLS:C3896609
28018523	822	831	expansion	T082	UMLS:C0205229
28018523	1014	1037	pulmonary function test	T058	UMLS:C0024119
28018523	1039	1042	PFT	T058	UMLS:C0024119
28018523	1073	1085	radiological	T058	UMLS:C0043299
28018523	1086	1099	rib fractures	T037	UMLS:C0035522
28018523	1344	1352	analysis	T062	UMLS:C0936012
28018523	1443	1452	pulmonary	T017	UMLS:C0024109
28018523	1453	1464	dysfunction	T038	UMLS:C0277785
28018523	1539	1557	fiducial placement	T058	UMLS:C3888577
28018523	1564	1575	CT guidance	T058	UMLS:C0475322
28018523	1583	1604	precipitously dropped	T033	UMLS:C0243095
28018523	1636	1649	bronchoscopic	T074	UMLS:C0179432
28018523	1650	1668	fiducial placement	T058	UMLS:C3888577
28018523	1681	1693	rib fracture	T037	UMLS:C0035522
28018523	1694	1698	risk	T033	UMLS:C0582456
28018523	1732	1744	rib fracture	T037	UMLS:C0035522
28018523	1759	1763	PFTs	T058	UMLS:C0024119
28018523	1859	1862	PFT	T058	UMLS:C0024119
28018523	1899	1908	follow-up	T058	UMLS:C1522577
28018523	2194	2211	treatment margins	T017	UMLS:C0229985
28018523	2232	2246	immobilization	T058	UMLS:C0020944
28018523	2248	2252	SBRT	T058	UMLS:C3896609
28018523	2258	2266	fiducial	T074	UMLS:C2826325
28018523	2274	2279	tumor	T038	UMLS:C0027651
28018523	2280	2288	tracking	T082	UMLS:C0546881
28018523	2348	2353	linac	T074	UMLS:C0023730
28018523	2361	2376	SBRT approaches	T058	UMLS:C3896609